Access to Medication Assisted Treatment (MAT)

December 27, 2022

Last week, Congress passed a massive Omnibus spending bill that includes the MAT Act which eliminates the so-called ‘x-waiver’;.  This means that individuals can access buprenophine for opioid use disorder without additional requirements, and that prescribers will no longer be limited in how many patients they can treat.   Specifically, this action eliminates the redundant requirement that practitioners apply for a separate waiver through the Drug Enforcement Administration (DEA) to prescribe buprenorphine for substance use disorder treatment.  Note:  After France took similar action to make buprenorphine available without a specialized waiver, opioid overdose deaths declined by 79 percent over a four-year period.

We owe a debt of thanks to Congressman Paul Tonko for his ongoing commitment and perseverance as he works tirelessly to increase access to Medicaid Assisted Treatment (MAT). 

Key health provisions (in the Omnibus Spending bill) that will help increase access to addiction treatment and related support services include:

See the attached document for more information on the Mainstreaming Addiction Treatment Act that was included in the Omnibus spending bill.  
Also see an important 12/1 article from Scientific American that speaks to unequal access to treatment: